KAT2B

Across TCGA pan-cancer cohorts, KAT2B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KAT2B data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KAT2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated KAT2B expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC and LUAD are the cancer types where KAT2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.738	0.328	.004	14	view →
LUAD	DFS	Quartile	All	0.885	0.486	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

KAT2B–PDAC (OS)

Open the PDAC breakdown →